Search: 
You do not have permission to access this chart.
Please Sign Up or Login
News for Savara Inc. (SVRA)
Newly released Crypto mining rig for Savara Inc. coins
minutes ago | Banggood.com
Everything Crypto on sale now!
58 minutes ago | Aliexpress.com
Savara Reports Second Quarter 2021 Financial Results and Provides Business Update
2 days ago | Business Wire
Savara (SVRA) Initiates Dosing in Pivotal Lung Disorder Study
a month ago | Zacks Investment Research
Savara Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial
a month ago | Business Wire
Implied Volatility Surging for Savara (SVRA) Stock Options
a month ago | Zacks Investment Research
Savara to Present at the Jefferies Virtual Healthcare Conference
2 months ago | Business Wire
Savara to Present at the Oppenheimer Rare & Orphan Disease Virtual Summit
3 months ago | Business Wire
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
3 months ago | Business Wire
Savara Reports First Quarter 2021 Financial Results and Provides Business Update
3 months ago | Business Wire
Do Options Traders Know Something About Savara (SVRA) Stock We Don't?
5 months ago | Zacks Investment Research
SVRA Stock Price Increases Over 10% Pre-Market: Why It Happened
5 months ago | Pulse2

About:

Savara Inc. operates as an orphan lung disease company. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

27

Address:

Savara Inc. Building III Suite 200 6836 Bee Cave Road Austin TX 78746 United States

Website:

Breathing new life into the treatment of autoimmune pulmonary alveolar proteinosis (aPAP)

Phone:

512-614-1848

Leave a comment

Your email address will not be published. Required fields are marked *